India's Most Valuable Companies 2023 edition · Source: Hurun India
Rank#448- Valuation
- ₹8,000 Cr
2022 #444 2021 #458
Revenue · FY 2025
₹3,869.17 Cr
▲ 4% YoY
Net profit · FY 2025
₹39.74 Cr
Net margin 1%
EBITDA · FY 2025
₹442.32 Cr
EBITDA margin 11.4%
Authorised capital
₹120.65 Cr
Registered with MCA
Paid-up capital
₹80.01 Cr
Issued & subscribed
Open charges
₹4,155.28 Cr
Satisfied ₹3,605.28 Cr
Company age
35 yrs
Est. 1991
Employees · EPFO
6,144
Provident fund records
About Cadila Pharmaceuticals Limited
Data last updated:
Cadila Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 February 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ1991PLC015132. Its GSTIN is 24AAACC6251E1Z5 (Gujarat). The company holds 26 GST registrations, of which 22 are active.
The company has an authorised share capital of ₹120.65 Cr and a paid-up capital of ₹80.01 Cr. It was formerly known as Nova Biotics (India) Pvt Ltd and Nova Biostic (India) Private Limited. It is led by directors including Rajiv Indravadan Modi (Managing Director) and Ramesh Ratilal Choksi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 14 August 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Cadila Corporate Campus Sarkhej Dholka Road Bhat, Ahmedabad, Gujarat, India – 382210.
As per the financials filed for FY 2025, the company reported a revenue of ₹3,869.17 Cr, a growth of 4% compared to the previous year. For the same year it recorded a net profit of ₹39.74 Cr (net margin 1%) and EBITDA of ₹442.32 Cr (EBITDA margin 11.4%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 10% over five years.
The company has about 6,144 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Cadila Pharmaceuticals Limited. As per MCA filings, the company has open charges of ₹4,155.28 Cr and satisfied charges of ₹3,605.28 Cr on record. Court records list 879 cases involving the company, including 422 filed by the company and 459 filed against it; 213 cases are pending. The company has 10 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹234.39 Cr; the latest was in March 2024. Its 10 peer companies in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Matrix Pharmacorp Private Limited with revenue of ₹4,422.21 Cr. The company has 13 MSME Form 1 returns on record between 2019 and 2024, listing 573 overdue payments to 135 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cadilapharma.com.
Company details
CIN U24231GJ1991PLC015132
Registration Number 015132
Incorporation Date 28 February 1991
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 14 August 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
Name history
Cadila Pharmaceuticals has undergone 3 name changes throughout its history. The company was previously known as Nova Biotics (India) Pvt Ltd, Nova Biostic (India) Private Limited, and Cadila Pharmaceuticals Private Limited. The current legal name is Cadila Pharmaceuticals Limited.
| Company Name | Status |
|---|---|
| Cadila Pharmaceuticals Limited | Current |
| Nova Biotics (India) Pvt Ltd | Previous |
| Nova Biostic (India) Private Limited | Previous |
| Cadila Pharmaceuticals Private Limited | Previous |
CIN history
Cadila Pharmaceuticals has one previous CIN (Corporate Identification Number): U24231GJ1991PTC015132. The current CIN is U24231GJ1991PLC015132, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231GJ1991PLC015132 | Current |
| U24231GJ1991PTC015132 | Previous |
Key People
Rajiv Indravadan Modi Managing Director Ramesh Ratilal Choksi Whole-Time Director Rajiv Rajiv Modi Director Recognitions & Rankings of Cadila Pharmaceuticals
Contact details
Cadila Pharmaceuticals Limited's registered office is in Ahmedabad, Gujarat. Its website is cadilapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressCadila Corporate Campus Sarkhej Dholka Road Bhat, Ahmedabad, Gujarat, India – 382210
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cadila Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Cadila Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Cadila Pharmaceuticals operates one associated brand: Cadila Pharmaceuticals Limited. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products are manufactured for multiple therapeutic areas. | cadilapharma.com |
Business activity
The main business activity of Cadila Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Cadila Pharmaceuticals Limited, buy the company report.
Financials of Cadila Pharmaceuticals Limited
FY 2024 filings availableCadila Pharmaceuticals Limited reported revenue of ₹3,869.17 Cr (up 4% YoY) for FY 2025.
Revenue · FY 2025
₹3,869.17 Cr ▲ 4%
Net profit · FY 2025
₹39.74 Cr margin 1%
EBITDA · FY 2025
₹442.32 Cr margin 11.4%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 4%
3 years · compounded
▲ 6%
5 years · compounded
▲ 10%
EBITDA CAGR growth
1 year
▼ 3%
3 years · compounded
▼ 6%
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 4% growth in the latest year. EBITDA fell 3% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹442.32 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹39.74 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.4% | ||||
| Net Profit Margin | 1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cadila Pharmaceuticals Limited, buy the company report.
Board of directors of Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals has 6 current directors and 34 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajiv Rajiv Modi Also directs: Irm Energy Limited, CPL Biologicals Private Limited, La Vie Biologicals Private Limited and 5 more | Director | 18 Jul 2024 | 2 Years 3 Months | Current |
| Subir Kumar Das Also directs: Irm Enterprises Private Limited, Transformers and Rectifiers (India) Limited, M & B Engineering Limited and 2 more | Additional Director | 30 Jun 2025 | 1 Years 4 Months | Current |
| Parul Nikunj Shah Also directs: Irm Enterprises Private Limited | Additional Director | 01 Dec 2023 | 2 Years 11 Months | Current |
| Rajiv Indravadan Modi | Managing Director | 28 Feb 1991 | 35 Years 8 Months | Current |
| Girdhar Prem Balwani | Director | 01 May 2017 | 9 Years 6 Months | Current |
| Ramesh Ratilal Choksi Also directs: CPL Biologicals Private Limited, La Vie Biologicals Private Limited, Gig - Irm Glass Insulators Private Limited and 5 more | Whole-Time Director | 07 Feb 2014 | 12 Years 8 Months | Current |
Peer comparison
Cadila Pharmaceuticals Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Matrix Pharmacorp Private Limited | ₹4,422.21 Cr (FY 2025) | 16378466.0% | Sangareddy, Telangana, India | |||
| Apl Healthcare Limited | ₹4,412.92 Cr (FY 2025) | 39.0% | Hyderabad, Telangana, India | |||
| Akums Drugs and Pharmaceuticals Limited | ₹4,170.28 Cr (FY 2025) | -1.0% | Delhi, India | |||
| J B Chemicals and Pharmaceuticals Limited | ₹3,956.31 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Glaxosmithkline Pharmaceuticals Limited | ₹3,895.14 Cr (FY 2025) | 9.0% | Mumbai, Maharashtra, India | |||
| Cadila Pharmaceuticals Limitedthis company | ₹3,869.17 Cr (FY 2025) | ₹39.74 Cr | 1% | 4.0% | 6,144 | Ahmedabad, Gujarat, India |
| Acg Associated Capsules Private Limited | ₹3,600.7 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India | |||
| Hetero Drugs Limited | ₹3,323.92 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Shreya Life Sciences Private Limited | ₹2,946.23 Cr (FY 2025) | 284.0% | Mumbai, Maharashtra, India | |||
| Amneal Pharmaceuticals Private Limited | ₹2,944.87 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Eris Lifesciences Limited | ₹2,912 Cr (FY 2025) | 43.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Cadila Pharmaceuticals Limited, buy the company report.
Auditor
Cadila Pharmaceuticals Limited is audited by MUKESH M. SHAH & CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MUKESH M. SHAH & CO. | FY 2024 | 106625W |
Shareholding
The shareholding of Cadila Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Cadila Pharmaceuticals Limited, buy the company report.
Charges & borrowings
Open charges
₹4,155.28 Cr
Satisfied charges
₹3,605.28 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Oct 2025 | 101173937 | Others | ₹5 Cr | Open | |
| 08 Sep 2025 | 101154887 | Indian Bank | ₹260 Cr | Open | |
| 16 Jun 2025 | 101136635 | Others | ₹216 Cr | Open | |
| 05 Jun 2025 | 101129931 | Others | ₹50 Cr | Open | |
| 27 Mar 2025 | 101083058 | Others | ₹100 Cr | Open |
To see the full charge records of Cadila Pharmaceuticals Limited, buy the company report.
Total charge records: 90 View all charges
Deals & funding
Cadila Pharmaceuticals Limited has 10 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹234.39 Cr; the latest was in March 2024.
Total deals
10
Secondary share transfers
5
Funding rounds
3
Rights issue
1
Convertible or debt financing
1
Disclosed funding
₹234.39 Cr
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2023 | Secondary share transfer | Undisclosed | Seller: IRM Trust, Irm Private Limited , CPL Infrastructure Private Limited, an individual |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: Inverika Bioresearch Private Limited , IRM Trust, La Vie Biologicals Private Limited Seller: La Vie Biologicals Private Limited , I.A Modi HUF 4, Rajiv I Modi HUF |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: I.A Modi HUF 4, IRM Trust, an individual Seller: Irm Trust & Rajiv Modi, Irm Trust & Monikaben G Modi, an individual |
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: Rajiv I Modi HUF, Mansi Trust & Rajiv I Modi, Irm Trust & Rajiv Modi Seller: Mansi Trust & I.a Modi, Irm Trust & I A Modi, I.A Modi HUF 1 |
| Dec 2013 | Secondary share transfer | Undisclosed | Buyer: Redefine Leisure Private Limited , Karnavati Engineering Private Limited , Irm Trust & I A Modi, an individual Seller: Irm Trust & Rajiv Modi, Irm Trust & Shilaben I Modi, 2 individuals |
To see the full deal history of Cadila Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cadila Pharmaceuticals Limited has 879 court cases on record: 422 filed by Cadila Pharmaceuticals, 459 filed against it. 213 cases are pending and 666 are disposed.
Total cases
879
Filed by the company
422
Filed against the company
459
Pending
213
Disposed
666
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 483 | 295 | 60 |
| High courts | 385 | 157 | 153 |
| Supreme Court | 11 | 7 | 0 |
Cases on record (5 of 879)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, SAS Nagar, Punjab | Civil suit | Filed against the company by Quixotic Pharma Pvt. Ltd. | Pending |
| District court, Ahmedabad, Gujarat | Court case (TMSUIT) | Filed by the company against Antila Generic Medicine Private Limited | Pending |
| District court, Ahmedabad, Gujarat | Court case (TMSUIT) | Filed by the company against Valentis Life Science Private Limited | Pending |
| District court, Ahmedabad, Gujarat | Commercial matter | Filed against the company by Shrinath Travel Agency Pvt. Ltd. Through Its Director Mr. Bhavesh Son of Nandlal Kabra | Pending |
| District court, Ahmedabad, Gujarat | Court case (CR EN) | Filed against the company by an individual | Pending |
To see the full case history of Cadila Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Cadila Pharmaceuticals Limited was last rated by Care on 28 Dec 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 28 Dec 2021 |
To see the full credit ratings and regulatory alerts of Cadila Pharmaceuticals Limited, buy the company report.
MSME payment delays
Cadila Pharmaceuticals Limited has 13 MSME Form 1 returns on record between 2019 and 2024, listing 573 overdue payments to 135 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 135)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Vaishali Agencies | |||
| Shako Plastick | |||
| Lifesurge Healthcare Private Limited | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Cadila Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Cadila Pharmaceuticals has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
2
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| CPL Biologicals Private Limited | U01403GJ2009PTC056409 | |
| CPL Pharmaceuticals Private Limited | U24299GJ2021PTC119244 |
To see the full group structure of Cadila Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Cadila Pharmaceuticals Limited has a workforce of 6,144 employees on its EPFO records as of Sep 23, 2025, across 11 active EPFO establishments.
Employee count
6,144
Active EPFO establishments
11
Employee growth
4.08%
GST
Cadila Pharmaceuticals has 26 GST registrations: 22 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
26
Active
22
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACC6251E1Z5 | Gujarat | Active | 01 Jul 2017 |
| 24AAACC6251E3Z3 | Gujarat | Active | 29 May 2025 |
| 03AAACC6251E1Z9 | Punjab | Active | 01 Jul 2017 |
| 05AAACC6251E1Z5 | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Cadila Pharmaceuticals Limited, buy the company report.
Recent activity
Cadila Pharmaceuticals Limited has 38 board changes on record since 1991: 9 appointments and 29 cessations. The latest: Subir Kumar Das was appointed as Additional Director on 30 Jun 2025.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 101173937 was registered on 17 Oct 2025.
Charges
A charge with Indian Bank amounted to Rs. 260.00 Cr with Charge ID 101154887 was registered on 08 Sep 2025.
Charges
A charge with Others of Rs. 1,969.35 Cr registered on 15 Apr 2024 with Charge ID 100916122 was modified on 25 Jul 2025.
Charges
A charge registered on 31 Mar 2022 via Charge ID 100554686 with Others was fully satisfied on 01 Jul 2025.
Appointed
Subir Kumar Das was appointed as Additional Director.
Charges
A charge registered on 27 Dec 2019 via Charge ID 100316138 with Others was fully satisfied on 23 Jun 2025.
Charges
A charge registered on 09 Apr 2018 via Charge ID 100174382 with Others was fully satisfied on 23 Jun 2025.
Charges
A charge with Others amounted to Rs. 216.00 Cr with Charge ID 101136635 was registered on 16 Jun 2025.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101129931 was registered on 05 Jun 2025.
Charges
A charge registered on 27 Jun 2023 via Charge ID 100748963 with Hdfc Bank Limited was fully satisfied on 25 Apr 2025.
Charges
A charge registered on 24 Mar 2023 via Charge ID 100704145 with Axis Bank Limited was fully satisfied on 16 Apr 2025.
Charges
A charge registered on 12 Apr 2019 via Charge ID 100265728 with Others was fully satisfied on 04 Apr 2025.
227 earlier events are in the company report.
News
Frequently asked questions
Cadila Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 February 1991 (35+ years old) and is registered under CIN U24231GJ1991PLC015132.
Cadila Pharmaceuticals has 6 current directors:
- Rajiv Indravadan Modi - Managing Director
- Ramesh Ratilal Choksi - Whole-Time Director
- Rajiv Rajiv Modi - Director
- Subir Kumar Das - Additional Director
- Parul Nikunj Shah - Additional Director
- Girdhar Prem Balwani - Director
The latest financial statements of Cadila Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 14 August 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Cadila Pharmaceuticals is 24AAACC6251E1Z5, registered in Gujarat. The company has 26 GST registrations in all, of which 22 are active and 4 are cancelled or inactive. Other active GSTINs include 24AAACC6251E3Z3 (Gujarat), 03AAACC6251E1Z9 (Punjab), 05AAACC6251E1Z5 (Uttarakhand).
The CIN (Corporate Identification Number) of Cadila Pharmaceuticals is U24231GJ1991PLC015132. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cadila Pharmaceuticals has 879 court cases on record: 422 filed by the company and 459 filed against it. 213 are pending. Most are in the district courts.
Cadila Pharmaceuticals was incorporated on 28 February 1991, making it 35+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Cadila Pharmaceuticals has 10 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹234.39 Cr; the latest was in March 2024.
The peers of Cadila Pharmaceuticals by revenue are Matrix Pharmacorp Private Limited, Apl Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, J B Chemicals and Pharmaceuticals Limited, Glaxosmithkline Pharmaceuticals Limited and 5 more, all in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Subir Kumar Das was appointed as Additional Director on 30 Jun 2025. Manvantkumar Shankerlal Rami ceased to be Director on 21 Nov 2024. Rajiv Rajiv Modi ceased to be Additional Director on 13 Aug 2024. Cadila Pharmaceuticals has 38 board changes on record in total.
Cadila Pharmaceuticals has 13 MSME Form 1 returns on record between 2019 and 2024, listing 573 overdue payments to 135 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Cadila Pharmaceuticals can be reached through the website cadilapharma.com. Its registered office is in Ahmedabad, Gujarat, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages